Divalproex Sodium Market Dynamics
Increasing prevalence of bipolar
disorders around the globe is propelling the Divalproex
Sodium Market growth. For instance, according to study published in JAMA
Psychiatry Journal 2012, in a combined sample of 61,392 adults from 11
countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and
0.4% for bipolar disorder-II and subthreshold bipolar disorder was 1.4%,
yielding a total prevalence estimates bipolar disorder spectrum of 2.4%
globally.
Moreover, rising patient pool
around the world affected with epilepsy and migraine headaches is also expected
to boost demand for divalproex sodium market significantly. For instance,
according to the World Health Organization 2018 key facts, around 50 million
people were globally affected with epilepsy, making it one of the most common
neurological disease, and around 80% of the people with epilepsy live in low-
and middle-income countries.
According to The Migraine Trust
Facts and Figures estimates, the global prevalence of migraine was 14.7% for
year 2013, that’s around 1 in 7 people. Furthermore, increasing awareness
regarding diseases and various government initiatives to prevent head migraine
is expected to propel growth of divalproex sodium market size.
However, black boxed warning
given by FDA due to the hepatotoxicity, pancreatitis, and high fetal risk
associated with the use of divalproex sodium tablet and other known adverse
reactions such as birth defects, neurobehavioral adverse effects, and suicidal
behavior are expected to restrain the divalproex sodium market growth.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1913
Divalproex sodium is a Food and
Drug Administrator (FDA) approved anti-epileptic drug used to treat migraine
headaches, manic episodes of bipolar disorders, and certain types of seizures.
Divalproex sodium is known for its anticonvulsant properties for the treatment
of epilepsy.
Divalproex sodium comes under
three dosage forms: capsule, tablet, and syrup. Divalproex sodium oral tablet
is available in brand-names, Depakote ER and Depakote. Divalproex sodium is
also used in various combinational therapies.
The recommended initial dosage of
Depakote for the treatment of bipolar disorders is 750 mg daily, whereas for
complex partial seizures, initial dosage starts with 10 to 15 mg/kg/day. Also,
recommended starting dose for migraine headache is 250 mg twice daily to
achieve therapeutic response.
Divalproex Sodium Market –
Regional Insights
Based on the region, the global
divalproex sodium market is segmented into North America, Europe, Latin America,
Asia Pacific, Middle East, and Africa. North America, specifically the U.S.
divalproex sodium market, holds a major global position among the geographies.
Owing to increased government initiatives and rising research and development
for the introduction of new product are expected to aid in growth of the
divalproex sodium market in the region.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/divalproex-sodium-market-1913
For instance, In 2011 The
National Quality Strategy (NQS) was launched as the national strategy for
quality improvement in health care, This was led by Agency for Healthcare
Research and Quality on behalf of the U.S. Department of Health and Human
Services (HHS). However, introduction of generic products by market giants in
the region is expected to hamper the market growth in the region. For instance,
in 2008, Mylan launched generic of Abbott's Depakote ER in the U.S.
Asia Pacific is expected to show
significant growth followed by Europe, owing to increased prevalence of
epilepsy and head migraine among the population in the region. For instance,
according to study published in the Journal of Global Health 2017, showed that
lifetime epilepsy prevalence was 1.99% in 1990 and 7.15% in 2015 among the
Chinese population.
Divalproex Sodium Market –
Competitive Landscape
Major players operating in the
global divalproex sodium market includes Zydus Pharmaceuticals, Inc., AbbVie
Inc., Mylan N.V., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Lupin
Limited, Orchid Chemicals & Pharmaceuticals Limited, Sun Pharmaceutical
Industries Ltd., Teva Pharmaceutical Industries Ltd., and Abbott Laboratories.
Market players are engaged in
adopting marketing strategies such as mergers, collaborations, induction of new
products to their portfolio, and acquisition, in order to obtain dominant
position in the market. For instance, in 2017, Zydus Cadila acquired Sentynl
Therapeutics, a U.S.-based pharma company specialized in marketing of products
in the pain management segment.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1913
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment